ViiV Healthcare

ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication

Retrieved on: 
Wednesday, March 6, 2024

“ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.

Key Points: 
  • “ACTG is thrilled to present this ground-breaking study at CROI,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
  • Participants received incentives and support to adhere to their daily oral medication to first achieve viral suppression and if successful, they were randomized to either receive long-acting injectable treatment every four weeks or continue taking daily oral medication.
  • The long-acting injectable treatment was more effective than the daily oral medication at maintaining virologic suppression and avoiding treatment-related discontinuation.
  • Twenty-eight participants receiving the long-acting injectable treatment experienced regimen failure (defined as virologic failure or treatment discontinuation), compared to 47 receiving daily oral medication.

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
Wednesday, March 6, 2024

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities

Retrieved on: 
Tuesday, March 5, 2024

Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.

Key Points: 
  • Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.
  • Dawn K. Smith HIV Prevention Clinical Fellowship.
  • The fellowship will provide comprehensive HIV training to non-infectious disease clinicians serving communities disproportionately affected by HIV.
  • Dawn K. Smith HIV Prevention Clinical Fellowship, experienced HIV clinicians will provide that training in priority populations and areas, with a special emphasis on pre-exposure prophylaxis (PrEP).”
    The Dr.

ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

Retrieved on: 
Monday, March 4, 2024

ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.

Key Points: 
  • ViiV Healthcare is conducting a registrational study of CAB-ULA in 2024 to further evaluate its use for the prevention of HIV in adults.
  • Future areas of study will include its potential use in combination with other medicines as a complete, ultra long-acting HIV treatment regimen.
  • ViiV Healthcare is a pioneer and leader in the development of long-acting HIV medicine, having already brought innovations through injectable therapies to the HIV community.
  • Based on these combined findings, ViiV Healthcare is no longer pursuing CAB 200 SC + rHuPH20 for ultra long-acting dosing.

ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

Retrieved on: 
Tuesday, February 6, 2024

The sheets allow people living with HIV to view the number of pills left and track their doses.

Key Points: 
  • The sheets allow people living with HIV to view the number of pills left and track their doses.
  • The FDA approved the Dovato blister pack on November 3, 2023.
  • ViiV Healthcare plans to offer the Dovato blister pack in some European markets in 2024.
  • ViiV Healthcare will continue to offer Dovato in the 30-count pill bottle.

Mallinckrodt Announces Board of Directors and Leadership Updates

Retrieved on: 
Friday, February 2, 2024

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as Mallinckrodt's President and Chief Executive Officer and a member of the Board.

Key Points: 
  • Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
    Siggi Olafsson Will Continue as President, CEO and Board Member
    DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.
  • Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
  • Select professional highlights of Mallinckrodt's new directors include:
    Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies.
  • With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton, Mallinckrodt's Board comprises seven directors.

COULD WE LIVE TO 200? AN ERA OF SUPEROPTIMIZED HEALTHCARE IS ON ITS WAY, ACCORDING TO NEW HAVAS REPORT

Retrieved on: 
Monday, January 8, 2024

"The Superhuman era we're living in speaks to the paramount meaning of health in people's lives," said Eric Weisberg, Global Chief Creative Officer, Havas Health & You.

Key Points: 
  • "The Superhuman era we're living in speaks to the paramount meaning of health in people's lives," said Eric Weisberg, Global Chief Creative Officer, Havas Health & You.
  • Superoptimized Me: The rise of longevity science, medical gyms, and concierge medicine services offers a supercharged yet tailored and luxury approach to wellness.
  • In this Superhuman era of consumer-driven health, each one of us has the power to create our own health ecosystem."
  • Access the full report here and follow Havas on Instagram and LinkedIn for the latest research insights.

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

Retrieved on: 
Wednesday, January 3, 2024

Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.

Key Points: 
  • Dr. Johns will oversee the discovery programs at Brii Bio and set the company's future pipeline strategy and priority.
  • "I am thrilled to reunite with Brian as our Chief Scientific Officer," said Zhi Hong, Ph.D., Chairman and Chief Executive Officer of Brii Bio.
  • Prior to joining Brii Bio, Dr. Johns served as the Chief Scientific Officer at HemoShear Therapeutics, Inc., where he led his team to novel targets and platforms in various disease areas.
  • "I am excited to join Brii Biosciences and contribute to the development of transformative therapies against infectious diseases," said Dr. Brian A. Johns.

Coalition of Leading U.S. Companies Reveals Joint Progress to Combat HIV Epidemic on Eve of World AIDS Day

Retrieved on: 
Thursday, November 30, 2023

Washington, D.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- As Congress debates potential deep cuts to federal funding for critical HIV programs on the eve of World AIDS Day, a growing number of leading private sector companies are stepping up to accelerate progress to end America’s ongoing HIV epidemic.

Key Points: 
  • Washington, D.C., Nov. 30, 2023 (GLOBE NEWSWIRE) -- As Congress debates potential deep cuts to federal funding for critical HIV programs on the eve of World AIDS Day, a growing number of leading private sector companies are stepping up to accelerate progress to end America’s ongoing HIV epidemic.
  • Forty businesses, anchored by several major employers and brands, have joined forces as part of U.S. Business Action to End HIV , a coalition of companies committed to ending the HIV epidemic in the U.S.
  • We are honored to do our part,” said Kevin Host, Senior Vice President of Pharmacy Operations at Walmart.
  • Over 1.2 million people in the United States are living with HIV, with nearly 35,000 new infections each year.

ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

Retrieved on: 
Wednesday, October 18, 2023

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.

Key Points: 
  • ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.
  • Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “Living well with HIV looks different for every individual, and we believe our upcoming presentations at EACS 2023 reflect our commitment and leadership to address the evolving needs of the HIV community.
  • Our latest data from our diverse portfolio and innovative pipeline explore real-world evidence that further evaluate the effectiveness, safety, and tolerability of 2-drug and long-acting regimens; new findings for broadly neutralizing antibodies; and long-term follow-up in heavily treatment-experienced individuals.
  • Here is a list of ViiV Healthcare-sponsored or supported studies being presented at EACS 2023: